Thrombospondin-1 and VEGF in inflammatory bowel disease

Libyan Journal of Medicine

Volumn 7, Issue 1, 2012, Pages 1-6

  Alkim, Canan ^a   Sakiz, Damlanur ^a   Alkim, Huseyin ^b   Livaoglu, Ayten ^a   Kendir, Tulin ^c   Demirsoy, Huseyin ^a   Erdem, Levent ^a   Akbayir, Nihat ^a   Sokmen, Mehmet ^a  

^a SISLI ETFAL TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b BAKIRKOY DR SADI KONUK TRAINING AND RESEARCH HOSPITAL   (Turkey)

^c Camlica Hospitalium ^*  (Turkey)

Author keywords

Colon cancer; Inflammatory bowel disease; iNOS; Thrombospondin 1; VEGF

Indexed keywords

INDUCIBLE NITRIC OXIDE SYNTHASE; THROMBOSPONDIN 1; VASCULOTROPIN;

ADULT; ARTICLE; CLINICAL ARTICLE; COLON BIOPSY; COLON MUCOSA; COLORECTAL CANCER; CONTROLLED STUDY; CROHN DISEASE; FEMALE; GENE EXPRESSION PROFILING; GENETIC CORRELATION; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MOLECULAR PATHOLOGY; NEOVASCULARIZATION (PATHOLOGY); PROTEIN EXPRESSION; ULCERATIVE COLITIS;

EID: 84856791883     PISSN: 19932820     EISSN: 18196357     Source Type: Journal    
DOI: 10.3402/ljm.v7i0.8942     Document Type: Article

References (42)

1. Neuman MG. Immune dysfunction in inflammatory bowel disease. Transl Res. 2007; 149: 173-86.
2. Pavlick KP, Laroux FS, Fuseler J, Wolf RE, Gray L, Hoffman J, et al. Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease. Free Radic Biol Med. 2002; 33: 311-22.
3. Witte MB, Barbul A. Role of nitric oxide in wound repair. Am J Surg. 2002; 183: 406-12.
4. Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol. 2004; 287: G7-G17.
5. Alkim C, Balci M, Alkim H, Dagli U, Parlak E, Tezel A, et al. The importance of peripheral immune cells in inflammatory bowel disease. Turk J Gastroenterol. 2007; 18: 82-8.
6. Danese S. Inflammation and mucosal microcirculation in inflammatory bowel disease: the ebb and flow. Curr Opin Gastroenterol. 2007; 23: 384-9.
7. Costa C, Incio J, Soares R. Angiogenesis and chronic inflammation: cause or consequence? Angiogenesis. 2007; 10: 149-66.
8. Pousa ID, Mate J, Gisbert JP. Angiogenesis in inflammatory bowel disease. Eur J Clin Invest. 2008; 38: 73-81.
9. Alkim C, Savas B, Ensari A, Alkim H, Dagli U, Parlak E, et al. Expression of p53, VEGF, microvessel density and cyclin-D1 in noncancerous tissue of inflammatory bowel disease. Dig Dis Sci. 2009; 54: 1979-84.
10. Griga T, May B, Pfisterer O, Mü ller KM, Brasch F. Immunohistochemical localisation of vascular endothelial growth factor in colonic mucosa of patients with inflammatory bowel disease. Hepatogastroenterology. 2002; 49: 116-23.
11. Toi M, Matsumoto T, Bando H. Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications. Lancet Oncol. 2001; 2: 667-73.
12. Zak S, Treven J, Nash N, Gutierrez LS. Lack of thrombospondin-1 increases angiogenesis in a model of chronic inflammatory bowel disease. Int J Colorectal Dis. 2008; 23: 297-304.
13. Jo WS, Mizukami Y, Duerr EM, Zukerberg LR, Chung DC. Wnt signaling can repress thrombospondin-1 expression in colonic tumorigenesis. Cancer Biol Ther. 2005; 4: 1361-6.
14. Saverymuttu SH, Camilleri M, Rees H, Lavender JP, Hodgson HJ, Chadwick VS. Indium 111-granulocyte scanning in the assessment of disease extent and disease activity in inflammatory bowel disease. A comparison with colonoscopy, histology and fecal indium 111-granulocyte excretion. Gastroenterology. 1986; 90: 1121-8.
15. King RJB, Coffer AI, Gilbert J, Lewis K, Nash R, Millis R, et al. Histochemical studies with a monoclonal antibody raised against a partially purified soluble estradiol receptor preparation from human myometrium. Cancer Res. 1985; 45: 5728-33.
16. Mattern J, Koomagi R, Volm M. Association of vascular endothelial growth factor expression with intratumoral microvessel density tumour cell proliferation in human epidermoid lung carcinoma. Br J Cancer. 1996; 73: 931-4.
17. Bahnassy AA, Zekri AN, El-Houssini S, El-Shehaby AMR, Mahmoud MR, Abdallah S, et al. Cyclin A and cyclin D1 as significant prognostic markers in colorectal cancer patients. BMC Gastroenterol. 2004; 4: 22.
18. Perner A, Rask-Madsen J. Review article: the potential role of nitric oxide in chronic inflammatory bowel disease. Aliment Pharmacol Ther. 1999; 13: 135-44.
19. Dijkstra G, Moshage H, van Dullemen HM, de Jager-Krikken A, Tiebosch AT, Kleibeuker JH, et al. Expression of nitric oxide synthases and formation of nitrotyrosine and reactive oxygen species in inflammatory bowel disease. J Pathol. 1998; 186: 416-21.
20. Linehan JD, Kolios G, Valatas V, Robertson DA, Westwick J. Immunomodulatory cytokines suppress epithelial nitric oxide production in inflammatory bowel disease by acting on mononuclear cells. Free Radic Biol Med. 2005; 39: 1560-9.
21. Kolios G, Rooney N, Murphy CT, Robertson DA, Westwick J. Expression of inducible nitric oxide synthase activity in human colon epithelial cells: modulation by T lymphocyte derived cytokines. Gut. 1998; 43: 56-63.
22. Roberts PJ, Riley GP, Morgan K, Miller R, Hunter JO, Middleton SJ. The physiological expression of inducible nitric oxide synthase (iNOS) in the human colon. J Clin Pathol. 2001; 54: 293-7.
23. Grisham MB, Pavlick KP, Laroux FS, Hoffman J, Bharwani S, Wolf RE. Nitric oxide and chronic gut inflammation: controversies in inflammatory bowel disease. J Investig Med. 2002; 50: 272-83.
24. Wei W, Kong B, Yang Q, Qu X. Hepatocyte growth factor enhances ovarian cancer cell invasion through downregulation of thrombospondin-1. Cancer Biol Ther. 2010; 9: 79-87.
25. Guo W, Dong ZM, Guo YL, Yang ZB, Kuang G, Shan BE. Correlation of hipermethylation of TSP1 gene with TGF-beta1 level and T cell immunity in gastric cardia adenocarcinoma. Ai Zheng. 2009; 28: 1298-303.
26. Rice AJ, Steward MA, Quinn CM. Thrombospondin 1 protein expression relates to good prognostic indices in ductal carcinoma in situ of the breast. J Clin Pathol. 2002; 55: 921-5.
27. Papadaki C, Mavroudis D, Trypaki M, Koutsopoulos A, Stathopoulos E, Hatzidaki D, et al. Tumoral expression of TXR1 and TSP1 predicts overall survival of patients with lung adenocarcinoma treated with first-line docetaxel-gemcitabine regimen. Clin Cancer Res. 2009; 15: 3827-33.
28. Zubac DP, Bostad L, Kihl B, Seidal T, Wentzel-Larsen T, Haukaas SA. The expression of thrombospondin-1 and p53 in clear cell renal cell carcinoma: its relationship to angiogenesis, cell proliferation and cancer specific survival. J Urol. 2009; 182: 2144-9.
29. Laklai H, Laval S, Dumartin L, Rochaix P, Hagedorn M, Bikfalvi A, et al. Thrombospondin-1 is a critical effector of oncosuppressive activity of sst2 somatostatin receptor on pancreatic cancer. Proc Natl Acad Sci USA. 2009; 106: 17769-74.
30. Iddings DM, Koda EA, Grewal SS, Parker R, Saha S, Bilchik A. Association of angiogenesis markers with lymph node metastasis in early colorectal cancer. Arch Surg. 2007; 142: 738-44.
31. Miyanaga K, Kato Y, Nakamura T, Matsumura M, Amaya H, Horiuchi T, et al. Expression and role of thrombospondin-1 in colorectal cancer. Anticancer Res. 2002; 22: 3941-8.
32. Tokunaga T, Nakamura M, Oshika Y, Tsuchida T, Kazuno M, Fukushima Y, et al. Alterations in tumour suppressor gene p53 correlate with inhibition of thrombospondin-1 gene expression in colon cancer cells. Virchows Arch. 1998; 433: 415-8.
33. Gutierrez LS. The role of thrombospondin-1 on intestinal inflammation and carcinogenesis. Biomarker Insight. 2008; 3: 171-8.
34. Griga T, Voigt E, Gretzer B, Brasch F, May B. Increased production of vascular endothelial growth factor by intestinal mucosa of patients with inflammatory bowel disease. Hepatogastroenterology. 1999; 46: 920-3.
35. Ferrante M, Pierik M, Henckaerts L, Joossens M, Claes K, van Schuerbeek N, et al. The role of vascular endothelial growth factor (VEGF) in inflammatory bowel disease. Inflamm Bowel Dis. 2006; 12: 870-8.
36. Gupta K, Gupta P, Wild R, Ramakrishnan S, Hebbel RP. Binding and displacement of vascular endothelial growth factor (VEGF) by thrombospondin: effect on human microvascular endothelial cell proliferation and angiogenesis. Angiogenesis. 1999; 3: 147-58.
37. Maeda K, Nishiguchi Y, Yashiro M, Yamada S, Onoda N, Sawada T, et al. Expression of vascular endothelial growth factor and thrombospondin-1 in colorectal carcinoma. Int J Mol Med. 2000; 5: 373-8.
38. Deban L, Correale C, Vetrano S, Malesci A, Danese S. Multiple pathogenic roles of microvasculature in inflammatory bowel disease: a jack of all trades. Am J Pathol. 2008; 172: 1457-66.
39. Scaldaferri F, Vetrano S, Sans M, Arena V, Straface G, Stigliano E, et al. VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology. 2009; 136: 585-95.
40. Danese S. VEGF in inflammatory bowel disease: a master regulator of mucosal immun-driven angiogenesis. Dig Liver Dis. 2008; 40: 680-3.
41. Danese S. Negative regulators of angiogenesis in inflammatory bowel disease: thrombospondin in the spotlight. Pathobiology. 2008; 75: 22-4.
42. Punekar S, Zak S, Kalter VG, Dobransky L, Punekar I, Lawler JW, et al. Thrombospondin 1 and its mimetic peptide ABT-510 decrease angiogenesis and inflammation in a murine model of inflammatory bowel disease. Pathobiology. 2008; 75: 9-21.